Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Chances Upped Supreme Court Hears Amgen/Sandoz Biosimilars Suit

Executive Summary

While an invitation for the top US government litigator to weigh in on Amgen Inc. v. Sandoz Inc. has prolonged the Supreme Court's decision on whether it will take up the case – creating a certain amount of limbo for the biosimilars marketplace – the request demonstrates the justices appear to be taking the matter seriously, upping the chances they may hear oral arguments potentially next spring.

Advertisement

Related Content

Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?
Court Probes Rationale Of Biosimilars' 180-Day Notice
Sandoz Dares SCOTUS To Unravel Biosimilars Law's Riddles
Court rules biosimilar 'patent dance' optional, but delays Zarxio
Novartis/Sandoz make history with 1st US biosimilar Zarxio

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel